Top Page
Jiangsu Recbio Technology Co., Ltd. Class H
(2179)
Jiangsu Recbio Technology Co., Ltd. Class H (2179) vs. iShares MSCI Hong Kong ETF (EWH)
Jiangsu Recbio Technology Co., Ltd. Class H Business Overview & Revenue Model
Jiangsu Recbio Technology Co., Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.11M | 27.00M | 30.38M | 5.33M | 6.20M | 1.46M |
| Gross Profit | 26.20M | 15.95M | 22.34M | 5.33M | 6.20M | 1.46M |
| EBITDA | -577.66M | -523.97M | -569.87M | -847.67M | -590.00M | -134.91M |
| Net Income | -653.91M | -562.39M | -571.96M | -719.20M | -657.56M | -179.40M |
Balance Sheet | ||||||
| Total Assets | 1.54B | 1.94B | 2.19B | 2.31B | 1.92B | 1.05B |
| Cash, Cash Equivalents and Short-Term Investments | 104.20M | 448.31M | 837.76M | 1.33B | 1.18B | 681.71M |
| Total Debt | 839.95M | 889.10M | 650.79M | 282.63M | 76.72M | 26.13M |
| Total Liabilities | 1.37B | 1.41B | 1.12B | 656.53M | 245.92M | 2.06B |
| Stockholders Equity | 177.63M | 529.32M | 1.07B | 1.66B | 1.67B | -1.01B |
Cash Flow | ||||||
| Free Cash Flow | -278.63M | -636.66M | -862.18M | -888.04M | -710.79M | -241.07M |
| Operating Cash Flow | -184.88M | -464.82M | -638.07M | -579.54M | -472.92M | -70.34M |
| Investing Cash Flow | -214.61M | -279.04M | 9.42M | -378.43M | 68.70M | -258.59M |
| Financing Cash Flow | 0.00 | 218.06M | 275.27M | 839.44M | 1.23B | 680.38M |
Jiangsu Recbio Technology Co., Ltd. Class H Technical Analysis
Jiangsu Recbio Technology Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$1.93B | 238.10 | 0.99% | ― | 9.41% | -32.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$2.35B | -11.90 | -55.33% | ― | -100.00% | 30.68% | |
42 Neutral | HK$8.41B | -18.58 | -95.84% | ― | -55.64% | -158.67% | |
41 Neutral | HK$1.90B | -2.69 | -129.05% | ― | ― | -18.99% | |
40 Underperform | HK$9.91B | -47.34 | -21.42% | ― | 240.05% | -140.09% |
Jiangsu Recbio Technology Co., Ltd. Class H Corporate Events
Jiangsu Recbio announced that China’s Center for Drug Evaluation has officially accepted the new drug application for its novel adjuvanted recombinant shingles vaccine REC610, which uses the company’s proprietary BFA01 adjuvant to boost VZV gE-specific cellular and antibody responses. The candidate has completed subject enrolment for a Phase III trial in adults aged 40 and above and showed favourable safety and strong immune responses comparable to GlaxoSmithKline’s Shingrix in exploratory head-to-head studies in China and the Philippines, underscoring its potential to address a sizeable shingles market in China, though the company cautions there is no assurance REC610 will ultimately be successfully developed or commercialised.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
Jiangsu Recbio Technology has announced a leadership reshuffle, with founder-executive Dr. Liu Yong stepping down as chairman of the board and head of the nomination committee to focus on other commitments while remaining as an executive director and general manager overseeing the company’s production, operations and overall management. The board has elected veteran pharmaceutical executive Xu Haoyu, chairman and president of Yangtze River Pharmaceutical Group and a prominent industry figure in China, as the new non-executive chairman; Xu and his family collectively hold significant indirect stakes in Recbio through multiple shareholding vehicles, a move that further tightens strategic ties with Yangtze River Pharmaceutical and may influence the company’s governance structure, strategic direction and access to industry resources.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
Jiangsu Recbio Technology Co., Ltd. has announced the current composition of its board of directors, led by chairman and non-executive director Xu Haoyu, and including a mix of executive, non-executive and independent non-executive directors such as Liu Yong, Wei Qifang and several academic and industry experts. The company has also detailed the structure and membership of its three key board committees—Audit, Remuneration and Appraisal, and Nomination—assigning independent director Xia Lijun and professors Gao Feng and Yuen Ming Fai to chair these committees, in a move that underscores its emphasis on governance, oversight and professionalized decision-making as it continues to develop its business in the biopharmaceutical industry.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
Jiangsu Recbio Technology Co., Ltd. announced that shareholders at its 19 December 2025 extraordinary general meeting approved a series of corporate governance changes, including the abolishment of its Supervisory Board and related amendments to its Articles of Association, which took effect immediately. All six resolutions were passed by poll with 100% of votes cast in favor, covering the appointment of one new non-executive director, two new executive directors, and revisions to the company’s rules for managing connected transactions and the working procedures of independent non-executive directors. The strong support from shareholders, who represented about 44.7% of issued shares at the meeting, signals clear backing for the board’s move to streamline governance structures and refine oversight mechanisms, potentially affecting how the company manages related-party dealings and board independence going forward.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
Jiangsu Recbio Technology Co., Ltd. has announced the current composition of its board of directors, comprising executive, non-executive and independent non-executive directors, with Dr. Liu Yong serving as chairman. The company has also detailed the membership and leadership of its three key board committees—Audit Committee, Remuneration and Appraisal Committee, and Nomination Committee—clarifying the oversight structure and governance responsibilities, which underscores its commitment to corporate governance and transparency for shareholders and other stakeholders.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
Jiangsu Recbio Technology Co., Ltd. announced the completion of the issuance of 143,112,702 fully paid Domestic Shares, increasing its total issued shares to 626,075,702. This issuance significantly altered its shareholding structure, granting Yangtze River Pharmaceutical a substantial stake and shifting the overall percentage of Domestic and H Shares, which could impact its market positioning and investor dynamics.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
Jiangsu Recbio Technology Co., Ltd. has announced an extraordinary general meeting scheduled for December 19, 2025, to discuss significant corporate governance changes, including the abolishment of the Supervisory Board and amendments to the Articles of Association. The meeting will also address the election of new directors and amendments to management rules, potentially impacting the company’s governance structure and operational strategies.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
Jiangsu Recbio Technology Co., Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement provides insights into the company’s governance structure, which is crucial for its strategic direction and operational management, potentially impacting stakeholder confidence and the company’s positioning in the biotechnology sector.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
Jiangsu Recbio Technology Co., Ltd. has established a Nomination Committee to enhance its governance structure by regulating the appointment of directors and senior management. This move aims to rationalize the board’s composition and improve the company’s operational efficiency, potentially impacting its industry positioning positively.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
Jiangsu Recbio Technology Co., Ltd. has established a Remuneration and Appraisal Committee to enhance its governance structure by formulating appraisal standards and remuneration plans for directors and senior management. This move aims to create a scientific and standardized incentive mechanism, potentially strengthening the company’s operational efficiency and stakeholder confidence.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
Jiangsu Recbio Technology Co., Ltd. has established an audit committee as part of its board to enhance decision-making, improve internal controls, and ensure effective supervision and management. The committee, composed mainly of independent non-executive directors with financial expertise, will oversee financial reviews, internal audits, and risk assessments, thereby strengthening the company’s governance structure.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
Jiangsu Recbio Technology Co., Ltd. has announced significant changes in its leadership structure, including the resignation of three directors and the appointment of new directors. The company is actively seeking to maintain gender diversity on its board and is committed to compliance with corporate governance standards. The new appointments are expected to bring fresh perspectives and leadership to the company, potentially impacting its strategic direction and market positioning.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
Jiangsu Recbio Technology Co., Ltd. has completed the industrial and commercial registration for its registered capital alteration, following the issuance of domestic shares to target subscribers. The company’s registered capital has increased from RMB482,963,000 to RMB626,075,702, and it has obtained a renewed business license. This change reflects a significant shift in the company’s shareholding structure, with domestic shares now accounting for a larger portion of the total share capital. These amendments to the Articles of Association were authorized by the Board of Directors and do not require further approval from the general meeting, indicating streamlined governance processes.
The most recent analyst rating on (HK:2179) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
Jiangsu Recbio Technology Co., Ltd. has received approval to expand its Drug Production License to include the recombinant shingles vaccine and its adjuvant components. This expansion enhances the company’s R&D and production capabilities, aligning with the growing market demand for shingles vaccines due to population aging. The approval signifies regulatory recognition of the company’s quality management and production standards, positioning it for future commercialization and strengthening its competitiveness in the biopharmaceutical industry.
The most recent analyst rating on (HK:2179) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
Jiangsu Recbio Technology Co., Ltd. has completed the payment and capital verification for its issuance of 143,112,702 domestic shares, priced at RMB5.59 each, resulting in net proceeds of RMB789,985,366.85. This successful issuance marks a significant step in the company’s financial operations, potentially enhancing its market positioning and providing additional resources for future growth initiatives.
The most recent analyst rating on (HK:2179) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.